Dendritic Cell-Based Cancer Immunotherapy
Revolutionizing cancer therapy on a global basis by developing TCR therapies with the potential to treat a wide range of cancer types and patients.
T Cell Receptor Analysis
Working on off-the-shelf cellular therapies that may offer the anticancer efficacy of autologous CAR-T treatments without the logistical complexity.
Aduro’s three proprietary technology platforms (Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies) have the potential to transform the ...
Advaxis’ Lm Technology uses live, attenuated bioengineered Listeria monocytogenes (Lm) bacteria to stimulate the immune system to view tumor cells as potentially ...
The company is focused on allergy research, prevention, and diagnosis.
Specific Immunotherapy Allergy Treatment
Alligator is a research-based biotechnology company developing antibody-based pharmaceuticals for cancer treatment ...
The company creates protein-based immunotherapies to treat cancer, autoimmune disorders, and other diseases.
Biologics. Amgen makes several therapeutic drugs that target serious disease. Many are derived from engineered monoclonal antibodies. Some target immune receptors.
Aminex Therapeutics, Inc., is a drug development company focused on discovery and development of a unique cancer drug therapy in the general category of cancer immunotherapies known as checkpoint ...
Uses modified antibodies to generate immunotherapeutics.
A biopharmaceutical company that focuses on Cardiovascular and Metabolic diseases, Oncology, and Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal diseases, ...
Atara Bio’s programs include T-cell product candidates and molecularly-targeted product candidates.
Avalon GloboCare Corp. is a healthcare management provider and biotechnology developer, dedicated to integrating and managing global healthcare resources, empowering high-impact biomedical ...
Stem Cell Technologies, Fully Human Biologics Manufacturing Cell Lines, Regenerative Medicine, CAR-T Immunotherapy & Cancer Treatment.
A biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Develops next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), CAR T cell therapy, and TCR ...
The cancer immunotherapy research group is focused on the next generation of T cell engineering and creating a pipeline of T cell product candidates (CAR T cells) to treat a wide variety of liquid ...
A biopharmaceutical company. They discover, develop, and deliver medicines to treat serious disease.
Small Molecules, Biologics, Vaccines, The pipeline is comprised of antibody-based therapies and other protein-based therapeutics that modulate the immune system or directly target tumors.
Designing next generation immunotherapies based on gene-edited CAR T-cells
Cellerant is developing novel innate and adaptive immunotherapies for oncology and blood-related disorders, including cell-based and antibody therapeutics.
CellSight's makes imaging tools to assess the response to immunotherapy..
Develops technology to activate the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells.
CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases.
Develops molecules to activate Toll like receptors. These can be used to stimulate the innate immune system.
Compugen, via its wholly-owned subsidiary Compugen USA, Inc., is developing therapeutic antibodies against selected target proteins both for cancer immunotherapy and antibody-drug conjugate ...
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Develops cancer immunotherapies, drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies based on Protease-Activated Antibodies, 'Probodies'
Immunotherapy treatment for prostate cancer.
Focused on therapies for cancer and inflammatory diseases
Activating the immune system to eradicate cancer. Focuses on regulatory T cells.
Committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics
Develops anti-cancer immunotherapies
Advancing first-in-class immunotherapy product candidates in oncology, as well as infectious and allergic diseases.